Welcome to our dedicated page for Mdxhealth Sa SEC filings (Ticker: MDXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MDxHealth SA (MDXH) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a foreign private issuer. MDxHealth files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These documents offer detailed information on its precision diagnostics business for prostate cancer and other urologic diseases, its financial condition, and material corporate events.
Form 20-F filings contain audited financial statements prepared under International Financial Reporting Standards (IFRS), along with sections on business description, risk factors, management’s discussion and analysis, and details of MDxHealth’s molecular diagnostic portfolio. For a company that derives revenue from clinical laboratory service testing and out-licensing of its DNA methylation platform and biomarkers, these annual reports are a key resource for understanding revenue composition, research and development spending, and acquisition accounting.
Form 6-K reports are used by MDxHealth to furnish press releases and interim reports, including quarterly and half-year financial results, acquisition announcements such as the Exosome Diagnostics transaction, amendments to earnout obligations related to the GPS prostate cancer business, management and board changes, and other significant updates. Some 6-K exhibits, such as interim reports, may be incorporated by reference into the company’s shelf registration statements on Form F-3, as noted in the filings.
On Stock Titan, MDXH filings are updated as they appear on EDGAR and are accompanied by AI-powered summaries that highlight the main points in complex documents. Users can quickly scan annual 20-F reports, interim 6-Ks, and related exhibits to identify information on MDxHealth’s precision diagnostics operations, risk disclosures, financing arrangements, and acquisition-related commitments, without reading each filing in full.